

## DAFTAR PUSTAKA

1. Roberta BA and Laxer Ronald M. Pediatric Mixed Tissue Disease. New York. Curr Rheumatol Rep. 2016.
2. Gary F, Ralph B, Sherine E, Gabriel, Iain B, James O, Harris. Kelley's Textbook of Rheumatology, 9th ed. Philadelphia: Pennsylvania. 2012.
3. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology. Oxford. 2006.
4. Gunnarsson R, Molberg O, Gilboe IM. The prevalence and incidence of mixed connective tissue disease. A national Ann Rheum Dis. 2011;70(6): 1047-51.
5. Patompong U, Cynthia S, Vaidehi R, Floranne C, Kevin G, Eric L. Epidemiology of mixed connective tissue disease 1985-2014: a population based study. HHS Public Access. 2016;4:1-16.
6. Gunnarsson R, Hetlevik SO, Lilleby V. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016;1:95-111.
7. Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of Pediatric Rheumatology, Sixth Edition. Saunders Elsevier Publishing. 2010.
8. Klein-Gitelman MS. Pediatric Mixed Connective Tissue Disease [Internet]. Medscape. 2018 [cited 22 March 2020]. Available from: <https://emedicine.medscape.com/article/1006966-overview#a6>
9. Sapkota Binita, Khalili Y A. Mixed Connective Tissue Disease. [Internet]. Medscape. 2021 [cited 21 December 2021]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542198/>

10. Ilowite NT, Laxer RM. Pharmacology and drug therapy. In Textbook of pediatric rheumatology. 6<sup>th</sup> ed. Saunders Elsevier; 2011. P. 71-123.
11. Kim KN. Treatment of Juvenile rheumatoid arthritis. Korean J Pediatr. 2010; 53 (11):936-41.
12. Bennett R M. Prognosis and treatment of mixed connective tissue disease [Internet]. Uptodate. 2020 [cited 23 March 2020]. Available from: <https://www.uptodate.com/contents/prognosis-and-treatment-of-mixed-connective-tissue-disease#H3>.
13. Tsai YY, Yang YH, Yu HH, Wang LC, Lee JH, and Chiang BL. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010;29(1):53-8.
14. Paradowska-Gorycka A, Stypińska B, Olesińska M, Felis-Giemza A, Mańczak M, Czuszyńska Z, et al. Association of HLA-DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. 2016. 87 (1):13-8.
15. Foster H, Jandial S. pGALS - paediatric Gait Arms Legs and Spine: a simple examination of the musculoskeletal system. *Pediatr Rheumatol*. 2013; 11: 44
16. Harris ED et al, Kelley's Textbook of Rheumatology, 7<sup>th</sup> ed. Philadelphia, Pennsylvania. 2005.
17. Imboden John B, Hellman David B, and Stone John B, Current Diagnosis and Treatment : Rheumatology, Mc Graw Hill. 2008.
18. Barrio J M et al, AB0640 Does Mixed Connective Tissue Disease Without Anti-U1rnp Exist?. BMJ. 2017.

19. Kim KN. Treatment of juvenile rheumatoid arthritis. *Korean J pediatr.* 2010;53 (11):936-41
20. Greidinger EL, Zang Y, Jaimes K et al. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. *Arthritis Rheum.* 2006;54:661-9.
21. Petty RE. Prognosis in children with rheumatic disease: Justification for consideration of new therapies. *Rheumatology.* 1999; 38 (8): 739-42.
22. Reiserter et al. Disease evolution in mixed connective nationwide prospective cohort study. *Arthritis Research & Therapy. Biomed Central.* 2017;19.
23. Perhimpunan Reumatologi Indonesia. *Diagnosis dan Pengelolaan Arthritis Reumatoid*, Perhimpunan Reumatologi Indonesia. Jakarta. 2014.
24. Sills EM, Barnett NK, Provost TT. Dermatomyositis - Collagen Vascular and Connective Tissue Disease. Dalam: Schacner LA, Hansen RC. *Pediatric Dermatology*, Edisi 2. Churchill and Livingstone Inc. 1995: 1119-1125
25. Falcini F, Vascular and connective tissue disease in the pediatric world. *Lupus.* 2004; 13: 77-84.
26. Murray KJ. Juvenile dermatomyositis: Advances in understanding and management. *Journal of Rheumatology.* 2003; 6:50-63.
27. Ravelli A, Ruperto N, Trail L, Felici E, Sala E, Martini A. Clinical assessment in juvenile dermatomyositis. *Autoimmunity.* 2006; 39: 197–203.
28. Richard K. Vehe, Mona M. Riskalla. *Collagen Vascular Diseases: SLE, Dermatomyositis, Scleroderma, and MCTD.* [Internet]. *Pediatric In Review*. Vol. 39 No. 10. 2018. [cited 2 March 2022]. Available from:

<http://www.pedworld.ch/ENTREE/RHUMATOLOGIE/2018-Collagenoses-PIR.pdf>

29. Gilliland BC. Systemic Sclerosis (Scleroderma) and Related Disorder In : Fauci AS (eds). Harrison's Principles of Internal Medicine 16<sup>th</sup> edition. New York. McGraw-Hill. 2005; 1979– 1990.
30. Setyohadi B. Sklerosis Sistemik Dalam Noer HMS, Waspadji S, Rachman AM dkk (eds). Buku ajar Ilmu Penyakit Dalam edisi ketiga. Jakarta, Balai Penerbit FKUI. 2000; 187–197.
31. Black CM. Scleroderma and fasciitis in childhood. UpToDate, 2002; 10(2): 998.
32. Hellmann DB. Arthritis & Musculoskeletal Disorders In: Tierney M, McPhee SJ, Papadakis MA (eds). Current Medical Diagnosis & Treatment 5<sup>th</sup> Ed. New York, Lange Medical Book / McGraw-Hill. 2006.
33. Paige W, Wolstencroft , Chung L, Shufeng Li, Livia Casciola-Rosen. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatol. 2018;154(1):44-51.
34. Sanner H. *Outcomes and prognostic factors in Juvenile Dermatomyositis Doctoral thesis by.* 2010.
35. Huber AM, Lang B, Blanc CMALE, Birdi N, Bolaria RK, Malleson P *et al.* Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. *Arthritis Rheum* 2000; **43**: 541–549.
36. Pistorio A, Ravelli A, Apaz MT, Saad-magalha C, Sato JDEO, Marcantoni MB *et al.* Health-Related Quality of Life of Patients With Juvenile Dermatomyositis : Results

- From the Paediatric Rheumatology International Trials Organisation Multinational Quality of Life. *Arthritis Rheum.* 2009; **61**: 509–517.
37. Rosa Neto NS, Goldenstein-Schainberg C. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. *Rev Bras Reumatol.* 2010; **50**: 299–312.
  38. Tiao J, Feng R, Bird S, Choi J.K, Dunham J et al., The Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Among Dermatologists, Rheumatologists, and Neurologists. *Br J Dermatol.* 2017 Feb; **176**(2): 423–430.
  39. Anyanwu CO, Fiorentino D, Chung L, Dzuong C, Wang Y, Okawa J et al., Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): characterizing disease severity and assessing responsiveness to clinical change. *Br J Dermatol.* 2015 Oct; **173**(4): 969–974.
  40. Paige W, Wolstencroft , Chung L, Shufeng Li, Livia Casciola-Rosen. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. *JAMA Dermatol.* 2018; **154**(1): 44–51.
  41. Sapkota Binita, AL Khalili Y. Mixed Connective Tissue Disease. *StatPearls.* 2022.
  42. Gameiro RS, Reis AIA, Grilo AC, Noronha C. Following leads: connecting dysphagia to mixed connective tissue disease. *BMJ Case Rep.* 2018. Doi:10.1136/bcr-2017-223699
  43. Ganra H. Proceeding Book PIKAB XV Improving Knowledge and Skill in Pediatric Health Care. Departemen/KSM Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Padjadjaran RSUP Dr. Hasan Sadikin. Bandung. 2018.